WATCHLONGEVITY

Saturday, June 20, 2026

STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential
DEVELOPING
Importance
62
Trust
76
Urgency
65
CLINICAL TRIAL✓ 2 outlets

STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential

Pfizer showed new details from a midstage trial of its obesity drug berobenatide, which the company bought from Metsera. The drug appears to work when given once a month instead of more often.

Analysis

Pfizer's once-a-month obesity drug shows promise in mid-stage testing. A monthly shot could be easier for patients than weekly options.

  • Pfizer showed new details from a midstage trial of berobenatide
  • Pfizer bought berobenatide from Metsera
  • Drug appears to work when given once a month
$PFE
berobenatidePfizerMetsera
STAT News — Pharma14d
Read
DEVELOPING
Importance
88
Trust
71
Urgency
65
DEAL

Pfizer matches Novo bid for obesity biotech Metsera as takeover battle rages - FT - MSN

Pfizer matched Novo Nordisk's offer to buy Metsera, a biotech company working on obesity drugs, as the two companies compete to acquire it. The bidding war shows how much pharmaceutical companies want to add new weight-loss treatments to their pipelines.

Analysis

Pfizer and Novo are fighting to buy Metsera. The winner gets new obesity drugs to challenge Lilly and grow in the booming weight-loss market.

  • Pfizer matched Novo Nordisk's offer to buy obesity biotech Metsera
  • Bidding war underway between Pfizer and Novo for Metsera
$PFE$NVO$MTSR
PfizerNovo NordiskMetsera
Pfizer Press Releases1mo
Read